New COVID booster vaccine shows promise in early trial

NCT ID NCT07134725

Completed ⭐️ VACCINE ⭐️ Sponsor: Federal University of Minas Gerais Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new COVID-19 booster vaccine called SpiN-Tec in 432 healthy adults aged 18 to 85 who had already received full vaccination and at least one booster. The vaccine was compared to approved boosters like Covishield and Comirnaty. The goal was to check safety and whether it triggers a strong immune response. The trial has been completed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SpiN-Tec MCTI UFMG vaccine (chimeric recombinant protein with adjuvant)
What this could lead to: If successful, this could provide a new booster option against COVID-19 that is safe and triggers a strong immune response.
What could go wrong: This is an early first-in-human trial with a small sample size. The vaccine may not prove as effective as existing boosters, and long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease infectious disease respiratory tract infectious disorder viral infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Faculdade de Medicina da UFMG - Unidade de Pesquisa Clínica em Vacinas (UPqVac)

Belo Horizonte, Minas Gerais, 30130-100, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.